Welcome to The Morning Dose, your one-stop shop for all things peptides, TRT, fitness, anti-aging, and everything in between.
Pour your morning coffee and lock in for this week’s groundbreaking news and rearch from the world of science-based biohacking, TRT, peptides and anti-aging.
In this week’s edition of The Morning Dose:
Let’s inject this.
Did someone forward you this email? Sign up here.
As research evolves in the realm of hormonal regulation and post-cycle support, alternative compounds to Tamoxifen are gaining attention for their unique mechanisms and potential benefits. This guide breaks down the top three alternatives researchers are examining in place of traditional SERMs like Tamoxifen.
Raloxifene has been studied for its ability to modulate estrogen receptors in a more selective way than Tamoxifen. Researchers are exploring its use in supporting bone density, reducing estrogenic effects, and managing hormone rebound post-cycle.
Clomiphene is another established SERM, often compared directly with Tamoxifen. It’s being studied for stimulating LH and FSH production to support natural testosterone recovery and mitigate hormonal suppression in test environments.
Derived from Clomiphene, Enclomiphene isolates the more active isomer, showing promise in clinical and experimental models for promoting endogenous testosterone production with fewer estrogenic side effects.
Curious which compound may lead the future of post-cycle research?
C60, or Carbon 60 Fullerene, is emerging as a fascinating molecule in longevity and oxidative stress research. Its unique structure allows it to act as a powerful antioxidant, sparking curiosity across experimental health models.
C60 is being studied for its ability to neutralize free radicals more efficiently than traditional antioxidants. Its spherical molecular structure makes it highly effective in targeting oxidative damage at the cellular level.
Animal models suggest C60 may extend lifespan and enhance mitochondrial function, promoting energy production and cellular resilience. Researchers are exploring its role in reducing inflammation, supporting neurological health, and preserving DNA integrity.
Studies continue to examine C60’s application in neuroprotection, immune modulation, and skin health, driven by its stability and bioactivity in lipid environments.
Curious about the potential of C60 in modern research?
Sunifiram, a potent nootropic from the ampakine family, continues to gain traction in the cognitive enhancement space. While not technically a racetam, its structural similarities and effects on learning and memory have made it a subject of growing scientific interest.
Sunifiram is being studied for its ability to enhance AMPA receptor activity, which plays a key role in synaptic transmission and long-term potentiation (LTP)—a core mechanism of memory formation. Research suggests it may offer increased alertness, faster learning, and improved information retention.
Studies explore how Sunifiram may impact acetylcholine and glutamate signaling, contributing to heightened mental clarity and focus. It’s also being evaluated for its possible mood-lifting effects via NMDA receptor activity and cholinergic pathways.
Due to its strength at microgram-level doses, Sunifiram is considered highly potent, making it a unique candidate for studies on ultra-low-dose cognitive modulators. Research emphasizes cautious experimental design due to its novel structure and limited long-term data.
Want to explore why Sunifiram is becoming a standout in cognitive research?
Join Our Private Community
If you want to join a community of like-minded individuals, be sure to join our private Facebook group.
You’ll be able to ask your questions, get feedback from our head coach, Daniel Louwrens, and interact with other members of the Muscle and Brawn community.
-The Morning Dose
PS – Have questions or suggestions? Hit reply and let us know what you think.
Disclaimer: This content is NOT medical advice. The information included in these emails is intended for entertainment and informational purposes only.